FUNCTIONAL INTERLEUKIN-2 RECEPTORS ARE EXPRESSED ON NATURAL KILLER-LIKE LEUKEMIC-CELLS FROM A DOG WITH CUTANEOUS LYMPHOMA

被引:21
作者
HELFAND, SC
MODIANO, JF
MOORE, PF
SOERGEL, SA
MACWILLIAMS, PS
DUBIELZIG, RD
HANK, JA
GELFAND, EW
SONDEL, PM
机构
[1] UNIV WISCONSIN, SCH VET MED, DEPT PATHOBIOL, MADISON, WI 53706 USA
[2] UNIV WISCONSIN, SCH MED, DEPT HUMAN ONCOL, MADISON, WI 53706 USA
[3] UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI 53706 USA
[4] UNIV WISCONSIN, SCH MED, DEPT GENET, MADISON, WI 53706 USA
[5] NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA
[6] UNIV CALIF DAVIS, SCH VET MED, DEPT PATHOL, DAVIS, CA USA
关键词
D O I
10.1182/blood.V86.2.636.bloodjournal862636
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We identified a dog with large granular lymphocytic leukemia and cutaneous lymphoma that exhibited constitutive expression of interleukin-2 (IL-2) receptors by the leukemic peripheral blood lymphocytes. The leukemic cells phenotypically resembled natural killer (NK) cells, and their surface IL-2 receptors were functional, as determined by the capacity to bind human recombinant IL-2 with high-affinity resulting in the transduction of proliferation signals and in the development of lymphokine-activated killer cell activity. These cells produced IL-2 spontaneously, and they may have maintained their proliferative state through an IL-2-dependent autocrine growth pathway, Our results indicate that neoplastic lymphocytes of syndromes that involve circulating leukemic cells with dermotropism can originate from NK-like cells. Additionally, the data also suggest that proliferative conditions such as these may be the result of the aberrant production of IL-2. Further, this case illustrates the potential for the use of hematopoietic malignancies in the dog as a suitable animal model for immune targeting of IL-2 receptors as a novel treatment approach for similar malignancies of human beings. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:636 / 645
页数:10
相关论文
共 76 条
[11]   DETECTION OF LYMPHOCYTES-T IN CANINE TISSUE EMBEDDED IN PARAFFIN WAX BY MEANS OF ANTIBODY TO CD3 ANTIGEN [J].
FERRER, L ;
FONDEVILA, D ;
RABANAL, R ;
RAMIS, A .
JOURNAL OF COMPARATIVE PATHOLOGY, 1992, 106 (03) :311-314
[12]  
GAZDAR AF, 1979, CANCER TREAT REP, V63, P587
[13]   IDENTIFICATION OF CANINE LYMPHOCYTE-T SUBSETS WITH MONOCLONAL-ANTIBODIES [J].
GEBHARD, DH ;
CARTER, PB .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 33 (03) :187-199
[14]  
GILLIS S, 1978, J IMMUNOL, V120, P2027
[15]   LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON - LYSIS OF NATURAL KILLER-RESISTANT FRESH SOLID TUMOR-CELLS BY INTERLEUKIN 2-ACTIVATED AUTOLOGOUS HUMAN PERIPHERAL-BLOOD LYMPHOCYTES [J].
GRIMM, EA ;
MAZUMDER, A ;
ZHANG, HZ ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) :1823-1841
[16]  
GRINDEM CB, 1985, J AM ANIM HOSP ASSOC, V21, P219
[17]   ADDITION OF INTERLEUKIN-2 INVITRO AUGMENTS DETECTION OF LYMPHOKINE-ACTIVATED KILLER ACTIVITY GENERATED INVIVO [J].
HANK, JA ;
WEILHILLMAN, G ;
SURFUS, JE ;
SOSMAN, JA ;
SONDEL, PM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 31 (01) :53-59
[18]  
HANK JA, 1988, CANCER RES, V48, P1965
[19]   INTERLEUKIN-2 RECEPTOR BETA-CHAIN GENE - GENERATION OF 3 RECEPTOR FORMS BY CLONED HUMAN ALPHA-CHAIN AND BETA-CHAIN CDNAS [J].
HATAKEYAMA, M ;
TSUDO, M ;
MINAMOTO, S ;
KONO, T ;
DOI, T ;
MIYATA, T ;
MIYASAKA, M ;
TANIGUCHI, T .
SCIENCE, 1989, 244 (4904) :551-556
[20]   CLINICAL AND IMMUNOLOGICAL EFFECTS OF HUMAN RECOMBINANT INTERLEUKIN-2 GIVEN BY REPETITIVE WEEKLY INFUSION TO NORMAL DOGS [J].
HELFAND, SC ;
SOERGEL, SA ;
MACWILLIAMS, PS ;
HANK, JA ;
SONDEL, PM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 39 (02) :84-92